Compare AbbVie Inc (ABBV) vs Hasbro, Inc. (HAS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Hasbro, Inc. — how do they compare? AbbVie Inc trades at $253.95 (market cap $449.91B), while Hasbro, Inc. trades at $75.68 (market cap $10.86B). The key difference: AbbVie Inc is far larger — about 41.4× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays the higher dividend (3.65%). Which is the better fit depends on your goals.
| ABBV | HAS | |
|---|---|---|
Market Cap | $449.91B | $10.86B |
Sector | Health | Consumer Cyclical |
52-Week High | $261.07 | $105.88 |
52-Week Low | $184.85 | $70.95 |
Enterprise Value | $513.38B | $13.12B |
Dividend Yield | 2.72% | 3.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Hasbro (HAS) trades at $76.73, down 4.27% on the day, with a bearish technical signal but oversold RSI readings suggesting potential reversal. The company reported a net loss of $322.4 million in 2025 despite revenue growth to $4.70 billion, with strong earnings beats in recent quarters. Analyst consensus is bullish with a $107.40 price target, while institutional sentiment remains mixed amid high debt levels and profitability challenges.
The outlook hinges on earnings execution and debt management, with upside from Wizards segment growth and digital initiatives. Key risks include sustained negative margins, $3.38 billion long-term debt burden, and consumer discretionary volatility. Near-term catalyst is Q2 2026 earnings on July 21, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →
